Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a leading life sciences manufacturer that is well positioned to capitalize on the growth trends in cell therapy and diagnostics markets. With a strong global presence and a focus on quality and regulatory compliance, the company is able to provide essential products and services for the pharmaceutical, biotech, academic, and diagnostic markets. Additionally, with a diversified revenue mix and a history of successful M&A, Bio-Techne is well positioned for long-term growth and market consolidation in the industry.

Bears say

Bio-Techne is a life sciences manufacturer that recently divested its loss-making business and reduced its brands from 10 to 3. While the company has a strong exposure to the cell therapy market, it is currently facing challenges in its growth and we expect its margins to be affected by the loss of high margin GMP reagent revenue due to customer timing. The company also has a limited linkage between sustainability metrics and executive compensation. We remain on the sidelines due to the current uncertainty and reduced visibility in the market.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.